Loading…
← CockpitCompetitor Analysis › ELN.MI El.En. S.p.A.Open in the cockpit ↗

El.En. S.p.A.ELN.MICompetitor analysis, valuation and peers

Italy · EUR·Health Care›Medical Specialties

Italian laser technology group making medical/aesthetic lasers, industrial cutting/marking lasers, and lasers for art restoration.

≈ A diversified Italian laser maker, like a smaller CoherentMomentum leader 82
Mkt cap
$1.46B
US dollars, full cap
Free float
58%
of shares outstanding
$/day
$947,403
20-day average traded
Fwd P/E
22.0×
forward earnings
ROIC−WACC
+11.3 pp
WACC 11.7%
Hurdle
+3 pp
Req g minus delivered
Close · EUR€16.55
1D+3.0%
1W+0.1%
1M+7.3%
3M+9.3%
6M+11.1%
YTD+18.9%
1Y+43.0%
ATR %3.6%
52w lowhigh6.2% off high

What El.En does

Italian laser technology group making medical/aesthetic lasers, industrial cutting/marking lasers, and lasers for art restoration.

Medical and aesthetic lasers, sold to clinics and distributors worldwide, are the larger part of sales, with industrial cutting and marking lasers following the manufacturing cycle. The group has grown by building up many small specialist subsidiaries.

In one line: A diversified Italian laser maker, like a smaller Coherent.

Products and services

  • Medical/aesthetic lasers (Deka)
  • Industrial laser cutting/marking
  • Cultural heritage restoration lasers
  • Surgical laser systems

Customers

  • Dermatology/aesthetic clinics
  • Industrial manufacturers
  • Museums/conservation institutes

Where it sits in the supply chain

  • Photonics
  • Laser systems
  • Medical, industrial & heritage…

What could go right

  • Aesthetic device demand growth
  • Industrial laser automation adoption

What could go wrong

  • Pricing competition in medical aesthetics
  • Industrial capex cyclicality

Moat: narrow (IP / patents, process know-how). Proprietary laser source technology and decades of niche application know-how.

Headquarters: Calenzano, Italy · Founded: 1981 · Employees: 1,412

Named competitors

El.En at a glance

Size El.En (ELN.MI) is an Italy Health Care company (Medical Specialties) with a market value of $1.46B, the 68th largest of 121 Italy companies the cockpit tracks. Shares closed at €16.55 on 18 Nov 2026.

Performance Over six months the shares gained 11.1%, against -7.0% for the median peer and +3.1% for the Italy market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 2.5% over the last twelve months (peer median +13.8%); the operating margin is 15.3% (peer median 6.8%).

Valuation It trades at 22.0× forward earnings against a peer median of 27.0× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 11.3 points above its cost of capital (11.7% WACC).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026ELN.MI 110Peer median 95
Six months, rebased to 100: El.En against the median of its 20 peers (local-currency closes).

El.En financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€552M€591M€566M€576M€674M
Revenue growth—+4%-2%-14%—
Gross profit€147M€142M€135M€138M€143M
EBITDA€94.8M€84.8M€84.4M€85.5M€87.2M
Net income€51.6M€43.4M€51.6M€48.2M€55.1M
Free cash flow€79.7M€60.1M€75.0M-€323,870-€15.3M
Capital expenditure€12.9M€11.6M€9.46M€13.7M€18.4M
Total debtn/a€38.1M€46.7M€73.6M€69.7M

Quarterly statements and history in the cockpit →

El.En competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%+20%300049300298PRCTCNMD6880166849ENOVVITR6885313010873005956699688198BFLY688758300633STAA8086INSPKMTSELN.MI6-month return →1-month return →
Up and to the right = strong over both horizons. El.En is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×300049300298CNMD6880166849ENOVVITR6885313010873005956699688198688758300633STAAINSPELN.MIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. El.En is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300049300298CNMD6880166849ENOVVITR3010876699STAAINSPELN.MIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. El.En is the large dot.

El.En competitors and peer comparison

Head to head with its named competitors (ELN.MI vs IPGP vs LBIRD.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
El.En ELN.MI$1.46B+11%+3%15%22.0×10.7%
IPG Photonics IPGP$2.80B-46%+15%5%32.4×25.5%
Lumibird LBIRD.PA$588M-5%+8%11%27.5×19.2%

How El.En compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

El.En against its 20 peers (data as of 18 Nov 2026)
MeasureELN.MIPeer medianRank in peer set
1-month return+7.3%-0.9%5th highest of 21
6-month return+11.1%-7.0%6th highest of 21
Distance from 52-week high-6.2%-28.4%highest of 21
Revenue growth (TTM)+2.5%+13.8%6th lowest of 21
Operating margin15.3%6.8%7th highest of 21
Forward P/E22.0×27.0×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)10.7%18.4%6th least demanding of 15
Growth delivered (Del g)+7.7%+17.4%4th lowest of 15
Hurdle (Req g minus delivered)+3.0 pp-6.8 pp5th most demanding of 15
ROIC minus cost of capital+11.3 pp-1.1 pp4th highest of 21
EV / EBITDA12.3×15.7×4th cheapest of 8
Net debt / EBITDA-1.9×-0.4×4th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a

Questions

Who are El.En's main competitors?
Named competitors: Cutera (private or unlisted), Candela Medical (private or unlisted), IPG Photonics (IPGP), Lumibird (LBIRD.PA). The cockpit's measured peer set (industry) also includes Inner Mongolia Furui Medical Science (300049.SZ), Sinocare (300298.SZ), PROCEPT BioRobotics (PRCT), CONMED (CNMD), Shanghai MicroPort Endovascular MedTech (688016.SS), Nihon Kohden (6849.T).
Is El.En expensive compared with its peers?
On forward p/e it trades at 22.0× against a peer median of 27.0×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has El.En stock performed?
Over six months to 18 Nov 2026 the shares returned +11.1% against -7.0% for the median peer; over one year +43.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.